Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care

Journal of the American Geriatrics Society

Volumn 49, Issue 5, 2001, Pages 577-584

  Lapane, Kate L ^a   Spooner, Josh J ^a   Mucha, Lisa ^b   Straus, Walter L ^b  

^a BROWN UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Gastrointestinal events; Nonsteroidal anti inflammatory agents; Nursing homes; Pharmacoepidemiology

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; DIFLUNISAL; ETODOLAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; SALSALATE; SULINDAC;

AGED; AGING; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GERIATRIC CARE; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NURSING HOME; PHARMACOEPIDEMIOLOGY; RISK ASSESSMENT;

AGE DISTRIBUTION; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DATABASES, FACTUAL; FEMALE; GASTROINTESTINAL DISEASES; HEALTH SERVICES RESEARCH; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REPORTING; LONG-TERM CARE; MAINE; MALE; MEDICAID; MEDICARE; MINNESOTA; NEW YORK; NURSING HOMES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; SOUTH DAKOTA; UNITED STATES; UNITED STATES CENTERS FOR MEDICARE AND MEDICAID SERVICES;

EID: 0035016015     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1532-5415.2001.49117.x     Document Type: Article

References (50)

1. Anti-arthritic medication usage: United States, 1991
2. Nonsteroidal anti-inflammatory drug usage patterns over a 10-year period for an ambulatory elderly population
3. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons
4. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: A cohort study
5. Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A meta analysis
6. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
7. The impact of research quality and study design on epidemiologic estimates of the effect of non-steroidal anti-inflammatory drugs on upper gastrointestinal tract disease
8. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
9. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation
10. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
11. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
12. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs
13. Cost of treating arthritis and NSAID-related gastrointestinal side effects
14. Adverse drug reactions and the elderly
15. The SAGE database: Introducing functional outcomes in geriatric pharmaco-epidemiology
16. Validity of diagnostic and drug data in standardized nursing home assessments: Potential for geriatric pharmacoepidemiology
17. Characteristics of the SAGE database: A new resource for research on outcomes in long-term care
18. Measuring health outcomes for older people using the SAGE database
19. MDS Cognitive performance scale
20. The MDS Cognition scale: A valid instrument for identifying and staging nursing home residents with dementia using the minimum data set
21. Validation of minimum data set cognitive performance scale: Agreement with the mini-mental state examination
22. The structure of social engagement among nursing home residents
23. Management of pain in elderly patients with cancer
24. Tacrine use in the nursing home
25. Prevalence, clinical correlates and treatment of hypertension in elderly nursing home residents
26. Elderly patients with perforated peptic ulcers: Factors affecting morbidity and mortality
27. Designing the national resident assessment instrument for nursing homes
28. Reliability estimates for the Minimum Data Set for nursing home resident assessment and care screening (MDS)
29. Corticosteroid use in peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs
30. Risk of upper gastrointestinal bleeding and perforation with individual anti-inflammatory drugs
31. Disability and severe gastrointestinal hemorrhage: A prospective study of community-dwelling older persons
32. Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis
33. Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs
34. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy
35. Risk factors for bleeding and fatal outcome in elderly patients with acute peptic ulcer bleeding
36. Prophylactic aspirin and risk of peptic ulcer bleeding
37. Final report on the aspirin component of the ongoing physician's health study
38. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Interim results
39. The effect of nonsteroidal antiinflammatory drug use on the use of gastroprotective medication use among people with arthritis in a managed care organization
40. Use of insurance claims in epidemiologic research: Identification of peptic ulcers, GI bleeding, pancreatitis, hepatitis, and renal disease
41. Patterns of prescription non-steroidal antiinflammatory drugs and gastroprotective agents
42. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs
43. NSAIDs and the elderly: Toxicity and economic implications
44. Correlates and management of nonmalignant pain in the nursing home
45. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2 - Specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
46. A multicenter randomized controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis